Andrew Schiff

Managing Partner

Dr. Schiff joined Aisling in 2000 and serves as one of the Managing Partners. Prior to Aisling, Dr. Schiff practiced internal medicine for six years at the New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine.

Dr. Schiff currently serves as a director of Aclaris Therapeutics, ARMGO Pharma, and Monte Rosa Therapeutics. His prior board service includes Adams Respiratory Therapeutics (acquired by Reckitt Benckiser), Agile Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics (acquired by Stiefel Laboratories), Bioenvision (acquired by Genzyme), CardioKine (acquired by Cornerstone), Cempra Pharmaceuticals, F2G, Harmony Biosciences, Miramar Labs (acquired by Sientra), Myogen (acquired by Gilead Sciences), PowerVision (acquired by Alcon), Quintiles (now IQVIA), SkinMedica (acquired by Allergan), Sirion Therapeutics (licenses acquired by Alcon), TransEnterix, Zavante Therapeutics (acquired by Nabriva) and ZELTIQ Aesthetics (acquired by Allergan). He is a longtime supporter and board member of the Visiting Nurse Service of New York.

Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia Business School, and his B.S. with honors in Neuroscience from Brown University.

Roles at Aisling Capital

  • Managing Partner

    Current role

My work style

How I prefer to work

Qualities I value in my colleagues

Sign up to see more about the team at Aisling Capital

My pet peeves

My communication style